Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients

First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.
Patients will proceed through a screening period, treatment period, and follow-up period of
approximately 4 months' duration. There will be 4 dose cohorts including active drug and
placebo dosing.

Inclusion Criteria:

- HCV-positive

- Nonresponder to standard-dose pegylated interferon-α-2a or -α-2b in combination with
standard-dose ribavirin

Exclusion Criteria:

- Human immunodeficiency virus (HIV)or hepatitis B surface antigen (HbsAg)

- Inadequate bone marrow, liver, and renal function

- Treatment with any IFN (interferon)-based or other experimental or antiviral therapies
within 30 days

- Other significant medical diseases

- Known alcohol or drug abuse within the past 12 months